Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer
Cancer Letters · 2024-05 · 589 · 216836
DOI: 10.1016/j.canlet.2024.216836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-05. Verfasst von Yi Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Interferons, Colorectal Neoplasms, Brain Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Despite the approval of immune checkpoint blockade (ICB) therapy for various tumor types, its effectiveness is limited to only approximately 15% of patients with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer (CRC). Approximately 80%-85% of CRC patients have a microsatellite stability (MSS) phenotype, which features a rare T-cell infiltration. Thus, elucidating the mechanisms underlying resistance to ICB in patients with MSS CRC is imperative. In this study, we demonstrate that ubiquitin-specific peptidase 4 (USP4) is upregulated in MSS CRC tumors and negatively regulates the immune response against tumors in CRC. Additionally, USP4 represses the cellular interferon (IFN) response and antigen presentation and impairs PRR signaling-mediated cell death. Mechanistically, USP4 impedes the nuclear localization of interferon regulator Factor 3 (IRF3) by deubiquitinating the K63-polyubiquitin chain of TRAF6 and IRF3. Knockdown of USP4 enhances the infiltration of T cells in CRC tumors and overcomes ICB resistance in an MC38 syngeneic mouse model. Moreover, published datasets revealed that patients showing higher USP4 expression exhibited decreased responsiveness to anti-PD-L1 therapy. These findings highlight an essential role of USP4 in the suppression of antitumor immunity in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
- Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, Guangdong, Chi…
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China; School of Biosciences and Technology, Chengdu…
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address: liaowt@sysucc.org.cn.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Sun Yat-sen University
- Science and Technology Foundation of Shenzhen City
- Fundamental Research Funds for the Central Universities
- Science, Technology and Innovation Commission of Shenzhen Municipality
Zitieren
APA
Zhou, Y., Li, H., Zhang, Y., Zhao, E., Huang, C., Pan, X., Shu, F., Liu, Z., Tang, N., Li, F., & Liao, W. (2024). Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer. Cancer Letters, 589, 216836. https://doi.org/10.1016/j.canlet.2024.216836
Vancouver
Zhou Y, Li H, Zhang Y, Zhao E, Huang C, Pan X, et al. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer. Cancer Letters. 2024;589:216836. doi:10.1016/j.canlet.2024.216836
BibTeX
@article{Zhou2024,
author = {Zhou, Yi and Li, Huali and Zhang, Yaxin and Zhao, Enen and Huang, Chengmei and Pan, Xingyan and Shu, Feng and Liu, Zhihao and Tang, Na and Li, Fengtian and Liao, Wenting},
title = {Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer},
journal = {Cancer Letters},
year = {2024},
volume = {589},
pages = {216836},
doi = {10.1016/j.canlet.2024.216836}
}
EUVIMED